%PDF-1.4
%
74 0 obj
<>
endobj
71 0 obj
<>
endobj
115 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-08T19:06:50Z
2024-03-29T05:41:12-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T05:41:12-07:00
application/pdf
Heather
2002-724.aug
uuid:12592e97-1dd2-11b2-0a00-190a277d8900
uuid:12592e99-1dd2-11b2-0a00-d30000000000
endstream
endobj
60 0 obj
<>
endobj
61 0 obj
<>
endobj
75 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 40 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
26 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 52 0 R/Type/Page>>
endobj
29 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 54 0 R/Type/Page>>
endobj
145 0 obj
[149 0 R]
endobj
146 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
[(arthritis. Results of a multicenter trial. )54.8 (Am J Med 1986;81:565-78.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Hamdy H, McKendry RJ, Mierins E, Liver JA. Low-dose)]TJ
1.675 -1.25 Td
(methotrexate compared with azathioprine in the treatment of)Tj
0 -1.25 TD
[(rheumatoid arthritis. )54.8 (A)-220.1 (twenty-four)19.7 (-week controlled clinical trial.)]TJ
T*
(Arthritis Rheum 1987;30:361-8.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Hochber)17.7 (g MC. )54.8 (Auranofin or D-penicillamine in the treatment of)]TJ
1.675 -1.25 Td
[(rheumatoid arthritis. )54.8 (Ann Intern Med 1986;105:528-35.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Rau R, Herborn G, Menninger H, Blechschmidt J. Comparison of)]TJ
2.175 -1.25 Td
(intramuscular methotrexate and gold sodium thiomalate in the )Tj
T*
(treatment of early erosive rheumatoid arthritis: 12 month data of a)Tj
T*
(double-blind parallel study of 174 patients. Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1997;36:345-52.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Meenan RF)79.7 (. )17.7 (The comparative ef)17.7 (ficacy and)]TJ
2.1381 -1.25 Td
(toxicity of second-line drugs in rheumatoid arthritis. Results of two)Tj
T*
[(metaanalyses. )54.8 (Arthritis Rheum 1990;33:1449-61.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (T)35 (ugwell P)110.7 (, Pincus )17.7 (T)74 (,)-0.1 ( )36.8 (Y)99.8 (ocum D, et al. Combination therapy with)]TJ
2.175 -1.25 Td
(cyclosporine and methotrexate in severe rheumatoid arthritis. N)Tj
0 Tc T*
(Engl J Med 1995;333:137-41.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875.1 (Petri H, Urquhart J. Channeling bias in the interpretation of drug)]TJ
2.175 -1.25 Td
[(ef)17.7 (fects. Stat Med 1991;10:577-81.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (W)79.9 (olfe F)79.7 (, Flowers N, Burke )17.7 (T)74 (,)-0.1 ( )54.8 (Ar)17.7 (guelles LM, Pettitt D. Increase in)]TJ
2.175 -1.25 Td
(lifetime adverse drug reactions, service utilization, and disease)Tj
T*
(severity among patients who will start COX-2 specific inhibitors:)Tj
T*
(quantitative assessment of channeling bias and confounding by)Tj
T*
(indication in 6689 patients with rheumatoid arthritis and)Tj
T*
(osteoarthritis. J Rheumatol 2002;29:1015-22.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Grobbee DE, Hoes )54.8 (A)79.8 (W)91.9 (. Confounding and indication for treatment)]TJ
2.175 -1.25 Td
(in evaluation of drug treatment for hypertension. BMJ)Tj
0 Tc 0 Tw T*
[(1997;315:1)36.9 (151-4.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (W)79.9 (olfe F)79.7 (,)-0.1 ( Kong SX, )17.7 (W)79.9 (atson DJ. Gastrointestinal symptoms and)]TJ
2.175 -1.25 Td
(health related quality of life in patients with arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2000;27:1373-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Fries JF)79.7 (, Spitz PW)91.7 (, )36.8 (Y)99.8 (oung DY)128.8 (. )17.7 (The dimensions of health outcomes:)]TJ
2.175 -1.25 Td
[(the Health )54.8 (Assessment Questionnaire, disability and pain scales. )]TJ
T*
(J Rheumatol 1982;9:789-93.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Fries JF)79.7 (, Spitz PW)91.7 (, Kraines RG, Holman HR. Measurement of)]TJ
2.175 -1.25 Td
[(patient outcome in arthritis. )54.8 (Arthritis Rheum 1980;23:137-45.)]TJ
30.825 45 Td
[(19.)-875.1 (W)79.9 (olfe F)79.7 (, Hawley DJ, )17.7 (W)39.8 (ilson K. )17.7 (The prevalence and meaning of)]TJ
2.175 -1.25 Td
(fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Meenan RF)79.7 (, Gertman PM, Mason JH, Dunaif R. )17.7 (The )54.8 (Arthritis)]TJ
2.175 -1.25 Td
[(Impact Measurement Scales. )54.8 (Arthritis Rheum 1982;25:1048-53.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Meenan RF)79.7 (. )17.7 (The )54.8 (AIMS approach to health status measurement:)]TJ
2.175 -1.25 Td
(conceptual background and measurement properties. J Rheumatol)Tj
0 Tc 0 Tw T*
(1982;9:785-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (Hawley DJ, )17.7 (W)79.9 (olfe F)79.7 (. Depression is not more common in )]TJ
2.175 -1.25 Td
(rheumatoid arthritis: a 10 year longitudinal study of 6,608)Tj
T*
(rheumatic disease patients. J Rheumatol 1993;20:2025-31.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (Hawley DJ, )17.7 (W)79.9 (olfe F)79.7 (.)-0.1 ( )54.8 (Anxiety and depression in patients with RA:)]TJ
2.175 -1.25 Td
[(A)-220.1 (prospective study of 400 patients. J Rheumatol 1988;15:932-41.)]TJ
-2.175 -1.25 Td
[(24.)-875.1 (Stata Corporation. Stata Statistical Software: Release 7.0. College)]TJ
2.175 -1.25 Td
[(Station, )17.7 (TX: Stata Corp.; 2001.)]TJ
-2.175 -1.25 Td
[(25.)-875.1 (Klein JP)110.7 (, Moeschber)17.7 (ger ML. Survival analysis: techniques for)]TJ
2.175 -1.25 Td
[(censored and truncated data. New )36.8 (Y)99.8 (ork: Springer; 1997:91-2.)]TJ
-2.175 -1.25 Td
[(26.)-875.1 (Cohen S, Cannon GW)91.7 (, Schif)17.7 (f M, et al. )17.7 (T)69.9 (wo-year)39.7 (, blinded,)]TJ
2.175 -1.25 Td
(randomized, controlled trial of treatment of active rheumatoid)Tj
T*
(arthritis with leflunomide compared with methotrexate. Utilization)Tj
T*
[(of Leflunomide in the )17.7 (T)35 (reatment of Rheumatoid )54.8 (Arthritis )17.7 (T)35 (rial)]TJ
T*
[(Investigator Group. )54.8 (Arthritis Rheum 2001;44:1984-92.)]TJ
-2.175 -1.25 Td
[(27.)-875.1 (Emery P)110.7 (, Breedveld FC, Lemmel EM, et al. )54.8 (A)-220.1 (comparison of the)]TJ
2.175 -1.25 Td
[(ef)17.7 (ficacy and safety of leflunomide and methotrexate for the )]TJ
T*
(treatment of rheumatoid arthritis. Rheumatology 2000;39:655-65.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (Schif)17.7 (f MH. Leflunomide versus methotrexate: )54.8 (A)-220.1 (comparison of the)]TJ
2.175 -1.25 Td
[(European and )54.8 (American experience. Scand J Rheumatol)]TJ
0 Tc 0 Tw T*
(1999;28:31-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(29.)-875.1 (Strand )17.7 (V)128.9 (, Cohen S, Schif)17.7 (f M, et al. )17.7 (T)35 (reatment of active rheumatoid)]TJ
2.175 -1.25 Td
(arthritis with leflunomide compared with placebo and methotrexate.)Tj
T*
[(Leflunomide Rheumatoid )54.8 (Arthritis Investigators Group. )54.8 (Arch Intern)]TJ
0 Tc T*
(Med 1999;159:2542-50.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(30.)-875.1 (W)79.9 (olfe F)79.7 (,)-0.1 ( Michaud K. )17.7 (T)69.9 (oward an acceptable definition of DMARD)]TJ
2.175 -1.25 Td
[(failure and abnormal health status in RA)-220.2 ([abstract]. )54.8 (Arthritis Rheum)]TJ
0 Tc T*
(2002;46 Suppl:S865.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
-0.00011 Tc 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:8)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1732)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
54 0 obj
<>stream
8;Z\7!H,e?#ikq,j?$9VCs:un]hZ\H8U*m.oe)ahi3_p3`d`W/a.L?DH@=aSj[-WO
fB:3.,Z=Pin&&.KGaoPmEn$=UCq#$h]F/'(*g(gjbESL.0c6X9-'IqZ@/%L9lLZK7
g@>G1:O>7J@o/WJj`uWS&Hf#(U-U?\[FB1p)p:4R&$fhtq+uuV61bp3*a-YjBpVHj
'T0@lkEnYqT$JgOX_QlhmT*Hnhc`C(=#]cZYLatd`JX$A()cs93JeGms-Qi^d:b?TNCK]5
"RL3b'')d*]<_
endstream
endobj
58 0 obj
[/Indexed/DeviceRGB 255 57 0 R]
endobj
57 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
81 0 obj
<>
endobj
77 0 obj
<>
endobj
98 0 obj
<>
endobj
120 0 obj
<>
endobj
78 0 obj
<>
endobj
90 0 obj
<>stream
HUiPSY~K, flVt[pi@dkid$$a 4 P FEP)mvwj\{lgIU}^uLNWι;;?c6,2ϭtQқFV8u#ynOby6x-sB/\ҭ00n۵
\1ǩo^$
(%U,M=bGoq
,I2
\(1[3$L4A.Lbtm
eBi5ŌH$0riBP H2\)d73 %RFde'DɢH(O;o%í͞1\$Vm`b[WB4LW:&Elfi)pƹA3Ta3ZfΞ;YKgx4߃7gќƹ+ qq;i_+'GRyq=aP-mdO/蛂!}alu}G,lzW,^q@;ֶ߲B2[7GҊ"m;b/B
0p*>Pί=|LA+9h\8~[[˱3ۙ7?":QP*5u]
wo6]